Peanut Allergy Market Comprehensive study by Key Players Mylan, ALK Abello, Stallargenes Greer

HTF Market Intelligence released a new research report of 124 pages on title 'Peanut Allergy: Opportunity Analysis and Forecasts to 2027' with detailed analysis, forecast and strategies. The study covers key regions that includes US, France, Germany, Italy, Spain, UK, Canada, and Australia and important players such as Aimmune Therapeutics, DBV Technologies, Prota Therapeutics, Cambridge Allergy, Sanofi etc.

Request a sample report @ https://www.htfmarketreport.com/sample-report/1390812-peanut-allergy-1

Summary
Peanut allergy is defined as a harmful health effect resulting from a specific and reproducible immune response following the ingestion of peanuts. While exposure to dietary antigens within the gastro-intestinal tract normally leads to oral tolerance, in certain individuals this mechanism fails. This results in sensitization and subsequent allergic responses towards innocuous food antigens. The most dangerous of these responses is an acute systemic reaction called anaphylaxis.

Peanut allergy has prevalence of 1-2.5% in developed nations and a low rate of remission-only around 20% in children. Though the specific etiology of peanut allergy is unclear, it is likely due to the interaction of genetic predisposition with environmental factors. Currently the only available strategy for managing peanut allergy long-term is avoidance and the treatment of acute reactions with injectable epinephrine. Some physicians have begun to offer their patients an investigational treatment known as experimental peanut oral immunotherapy. Though these grassroots efforts can be effective in desensitizing patients to peanut, they lack standardization and regulatory agency approval, thus making it difficult to ensure the safety of the treatment. With a complete absence of approved therapies available, peanut allergy is an indication with extremely high unmet need.

Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/1390812-peanut-allergy-1

Growing at a compound annual growth rate (CAGR) of 111% over the 10-year forecast period, in 2027 peanut allergy sales are projected to reach over $4.5 billion. The majority of sales (88%) will come from the US. This is mainly due to the US having a large population of potential patients (estimated 3,000,000 probable diagnosed prevalent cases), an elevated expected price tag for new therapies (nearly 5-7 times that of the other geographies), and a higher expected treatment rate (based on good accessibility to allergy specialists).

Aimmune's AR-101, is expected to be the market leader among the four peanut immunotherapy products released during the forecast, period, capturing over 67% of the peanut allergy market in 2027, worth an estimated $3.0B. Second in sales is DBV Technologies' Viaskin Peanut, which is projected to capture 32% of the peanut allergy market in 2027, totaling nearly $1.4B in sales. Finally, sales for Prota Therapeutics' and Camallergy's products, PPOIT and CA-002, together are only expected to total 1%. This estimate is based on GlobalData's assumption that within the forecast period these therapies will each only be released in one geography-Australia and the 5EU respectively.

Scope

- Overview of peanut allergy including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized peanut allergy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the peanut allergy therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global peanut allergy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global peanut allergy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global peanut allergy therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global peanut allergy therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=1390812

Key Questions Answered

- The projected entry of four new peanut immunotherapy products during the forecast period is expected to spur intense growth within the peanut allergy market. How are these immunotherapy products similar and different? What are the strengths and weaknesses of the small biotech and start-up companies launching these therapies? Which of these drugs will have the highest peak sales, and why?
- Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are considerably high unmet needs within the peanut allergy indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
- The peanut allergy market is likely to remain a dynamic, growing space throughout the forecast period and beyond. What are the main R&D trends in this market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early stage clinical development?

Companies Mentioned in the Report:

Aimmune Therapeutics, DBV Technologies, Prota Therapeutics, Cambridge Allergy, Sanofi, Regeneron, AnaptysBio, Mylan, ALK Abello, Stallargenes Greer, Astellas Pharma, Immunomic Therapeutics, HAL Allergy, Aravax, Immune Design, ASIT Biotech, Allakos, BioLingus, Allergy Therapeutics, Sementis, Selecta Biosciences, Intrommune Therapeutics, Adverum Biotechnologies, Virtici, Alfacyte, Perosphere

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Peanut Allergy: Executive Summary 7
3 Introduction 16
3.1 Catalyst 16
3.2 Related Reports 17
3.3 Upcoming Related Reports 17
4 Disease Overview 18
5 Epidemiology 22
6 Current Treatment Options 3

....Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1390812-peanut-allergy-1

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA - 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the "Accurate Forecast" in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their "Goals & Objectives".

This release was published on openPR.